Health Care · Pharmaceutical Preparations · Nasdaq · CIK 1664710 · FYE Dec 31 · Prices AT CLOSE 2026-07-30 (USD) — end-of-day, never a live or intraday quote
Last $10.22Day +2.51%Mkt cap $377MP/E (FY) 4.3×1Y −29.4%Off 52W high −54.7%Vol (1Y) 49.3%
Daily closing price, split-adjusted to the current basis; 3y shown of 1,361 bars on file. Sampled to 240 points — every point is a real close, none averaged. Price return, not total return (dividends excluded). Source marketstack.
| Short interest2.8% of sh out |
| Days to cover4.1d |
| 13F net flow (QoQ)−2.48% |
| Top-10 13F concentration50.9% |
| Next report (est.)2026-08-13 |
Short interest is FINRA semi-monthly, settlement 2026-07-15. 13F figures are quarterly filings, period 2026-Q1 — a lower bound on true ownership.
| P/E (FY)4.3× |
| Sales (TTM)$32.7M |
| Earnings (TTM)-$85.1M |
| ROE19.9% |
| Net margin35.7% |
| ROIC468.0% |
Screener basis: ratios from the latest reported fiscal year; Sales/Earnings are trailing twelve months in the reporting currency (USD). The P/E is a trailing FULL-YEAR P/E, not TTM. Missing lines are absent from the filings, never imputed.
| YTD−49.8% |
| 1Y−29.4% |
| 3Y−75.6% |
| 5Y−72.2% |
| Since incept. (ann.)−28.9% |
Total return through 2026-07-30 · series begins 2021-02-22. Only the windows this history actually covers are shown.
| Ann. volatility (1Y)49.3% |
| Ann. volatility (3Y)68.2% |
| Sharpe (1Y)−0.47 |
| Sharpe (3Y)−0.20 |
| Max drawdown (1Y)−54.6% |
| Max drawdown (3Y)−86.5% |
| Beta (3Y vs SPY)1.55 |
Daily simple returns, annualized; drawdown is peak-to-trough within the window. Beta is the OLS slope of monthly returns on SPY's over three years. Each figure is labeled by the window it was measured over — they are not comparable across windows.
| Manager | Shares | Value | % sh out | QoQ |
|---|---|---|---|---|
| BlackRock, Inc. | 2.4M | $27M | 6.37% | +5.3% |
| Nantahala Capital Management, LLC | 1.4M | $15M | 3.59% | +277.5% |
| VANGUARD CAPITAL MANAGEMENT LLC | 831,421 | $9M | 2.20% | new |
| ORBIMED ADVISORS LLC | 759,155 | $8M | 2.01% | −5.6% |
| Qube Research & Technologies Ltd | 724,926 | $8M | 1.91% | −7.5% |
| JACOBS LEVY EQUITY MANAGEMENT, INC | 706,071 | $8M | 1.86% | −8.1% |
| FEDERATED HERMES, INC. | 689,229 | $8M | 1.82% | +5.3% |
| VANGUARD PORTFOLIO MANAGEMENT LLC | 682,043 | $8M | 1.80% | new |
Reported 13F long positions as filed for 2026-Q1 (change vs 2025-Q4). 13F covers US-listed long equity only — the sum is a LOWER BOUND on institutional ownership, never a total.
| Period end | Reported | EPS | EPS YoY | Revenue | Rev YoY |
|---|---|---|---|---|---|
| 2026-03-31 | 2026-05-14 | −$1.21 | −133.4% | $32,000 | −100.0% |
| 2025-12-31 | 2026-03-04 | — | — | $380,000 | — |
| 2025-09-30 | 2025-11-05 | −$0.18 | — | $14.1M | — |
| 2025-06-30 | 2025-08-06 | −$0.76 | — | $18.2M | — |
EPS and revenue as reported in this filer's own XBRL — our extraction of the filings, not a vendor consensus feed, and never a beat/miss claim (we carry no estimates). YoY compares the same fiscal quarter a year earlier. Next report 2026-08-13 is ESTIMATED from filing cadence (median gap 91d) — not company-confirmed.
Reportable 100%
business segments · each slice's share of TAGGED segment revenue in the latest annual filing (XBRL, as filed). Untagged revenue is excluded from the denominator, so slices need not sum to consolidated sales.
